The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Monkshood, currently 7% of my pension is in this share so I clearly believe in the product. But I no longer take the AN/company forecasts seriously; just let it roll. Lockdown started on 23rd March, 7 working days before FDA submission date and they had not finished drawing blood samples let alone testing them , doing the analysis, writing up the report and eventually finalising the submission. And all because of the lockdown. I think (hope) the technology is a winner and will be approved but don't even bother reading most RNS publications now. I will learn the results one day from the share price. Good luck.
Sharesting or anyone, Richard Griffiths, the largest private investor recently sold all his shares. Now the largest institutional investor is thought to be strenuously selling shares.... Question for the next pub quiz - why do professional investors sell off shares with the best prospects when they need cash? Why not just dump the ones with no prospects medium term?
CB, fantastic news must be an understatement. As the trial has been launched and first patients next week should Faron be notifying by RNS 7 am Monday? The company must realise it is price sensitive. Or do you think they will try to keep schtum for some reason?
Thanks Tiptree.
The earlier Recovery trial protocol, dated 4th April shows Interferon as one of the treatment arms. " Arm 3: Interferon-?-1a. Nebulized solution of IFN-ß1a 6MIU (0.5ml of a solution
containing 12MIU/ml) once-daily for 10 days or until discharge. "
This is the treatment arm which has been dropped in favour of Azithromycin in the current protocol.
As the original interferon beta was nebulized, I assumed it was the Synairgen product. I also have shares in Faron which supplies injectable Interferon used in the REMAP-CAP trial.
SG, Recovery trial webpage states that Interferon has been dropped
Item 2 on update states:
"Adding azithromycin as an arm to the trial (replacing interferon beta)"
I assume that is not good news but very happy to be proved wrong.